Lanean...
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous studies suggested that TDF toxicity is higher when it is co-administered with ritonavir-boosted proteas...
Gorde:
| Argitaratua izan da: | J Int AIDS Soc |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
International AIDS Society
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224916/ https://ncbi.nlm.nih.gov/pubmed/25394078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19571 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|